AMRUTANJAN:NSE-Amrutanjan Health Care Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 834.55

Change

0.00 (0.00)%

Market Cap

INR 24.15B

Volume

0.01M

Avg Analyst Target

N/A

Avg User Target

INR
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Amrutanjan Health Care Limited (AMRUTANJAN) Stock Analysis:
Based on the Amrutanjan Health Care Limited stock forecasts from 0 analysts, the average analyst target price for Amrutanjan Health Care Limited is not available over the next 12 months. Amrutanjan Health Care Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Amrutanjan Health Care Limited is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Amrutanjan Health Care Limited’s stock price was INR 834.55. Amrutanjan Health Care Limited’s stock price has changed by +2.65% over the past week, -8.38% over the past month and +11.12% over the last year.

About

Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms, non-alcoholic beverages, and sanitary napkins. The company operates through OTC Products, Beverages, and Others segments. It provides pain management products comprising pain balms and roll-ons ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-21 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

INR2,190.59B 34.10 21.22
DIVISLAB:NSE Divi's Laboratories Limited

N/A

INR1,137.60B 44.30 31.87
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

INR705.17B 29.99 13.11
PEL:NSE Piramal Enterprises Limited

N/A

INR460.16B 37.13 11.89
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

N/A

INR445.45B 36.53 18.30
ALKEM:NSE Alkem Laboratories Limited

N/A

INR359.02B 21.82 15.90
AUROPHARMA:NSE Aurobindo Pharma Limited

N/A

INR326.92B 11.40 6.57
LAURUSLABS:NSE Laurus Labs Limited

N/A

INR304.55B 36.92 22.36
LUPIN:NSE Lupin Limited

N/A

INR290.72B 25.10 34.81
IPCALAB:NSE IPCA Laboratories Limited

N/A

INR250.01B 27.26 17.53

ETFs Containing AMRUTANJAN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.89% 67% D+ 46% F
Dividend Return 0.11% 7% F 4% F
Total Return -10.78% 69% D+ 46% F
Trailing 12 Months  
Capital Gain 11.12% 83% B 46% F
Dividend Return 0.61% 62% D- 35% F
Total Return 11.73% 70% C- 46% F
Trailing 5 Years  
Capital Gain 129.08% 79% C+ 79% C+
Dividend Return 3.20% 63% D 44% F
Total Return 132.29% 79% C+ 79% C+
Average Annual (5 Year Horizon)  
Capital Gain 32.83% 61% D- 72% C-
Dividend Return 0.60% 58% F 45% F
Total Return 33.43% 59% F 72% C-
Risk Return Profile  
Volatility (Standard Deviation) 37.29% 75% C 74% C
Risk Adjusted Return 89.66% 92% A- 95% A
Market Capitalization 24.15B 56% F 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 38.57 24% F 27% F
Price/Book Ratio 9.60 10% F 10% F
Price / Cash Flow Ratio 26.90 29% F 24% F
EV/EBITDA 23.81 23% F 26% F
Management Effectiveness  
Return on Equity 29.46% 93% A 90% A-
Return on Invested Capital 27.29% 96% A 95% A
Return on Assets 16.52% 96% A 96% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield 0.56% 36% F 35% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.65 64% D 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.